ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Regulation FD Disclosure
ME Staff 8-k
ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Files An 8-K Regulation FD DisclosureItem 7.01. Regulation FD Disclosure.
On December7, 2017, Aralez Pharmaceuticals Inc., a company formed under the laws of the Province of British Columbia, Canada (the “Company”), has made available a presentation entitled “Corporate Overview& Business Strategy” through the “Investors” section of the Company’s website (http://www.aralez.com) under the “Presentations& Webcasts” tab. The presentation will be available for future review for two weeks after December7, 2017. The information contained in, or that can be accessed through, the Company’s website is not a part of this filing.
About ARALEZ PHARMACEUTICALS INC. (NASDAQ:ARLZ) Aralez Pharmaceuticals Inc. is a Canada-based specialty pharmaceutical company. The Company focuses on acquiring, developing and commercializing products in cardiovascular, pain and other areas. The Company’s products include Fibricor, Cambia, Fiorinal, Fiorinal C, Soriatane, Bezalip SR, NeoVisc, Uracyst, Durela, Proferrin, Resultz and Collatamp G. Its development products include YOSPRALA and Bilastine. Fibricor (fenofibric acid) is indicated as a complementary therapy along with diet for the treatment of hypertriglyceridemia, and as a complementary therapy along with diet to reduce elevated low-density lipoprotein cholesterol (LDL-C), total cholesterol (Total-C), triglycerides (TG) and apolipoprotein B (Apo B). Fibricor is also used to increase high-density lipoprotein (HDL) cholesterol (HDL-C) in patients with hypercholesterolemia or mixed dyslipidemia. Cambia (diclofenac potassium for oral solution) is a non-steroidal anti-inflammatory drug (NSAID).